Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; SomatostatinomaInterventions: Drug: regorafenib; Other: laboratory biomarker analysisSponsors: University of Southern California; National Cancer Institute (NCI)Not yet recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoid Tumor | Carcinoma | Gastroenterology | Neurology | Research